Virax Biolabs Group Ltd (VRAX) Form 6-K — Jul 16, 2026
Virax Biolabs released a shareholder update detailing its fiscal 2026 annual report, which showed a strengthened balance sheet with $6.4 million in cash and total assets of $8.3 million as of March 31, 2026. The company reported a net loss of $5.0 million for the fiscal year, an improvement from the $6.1 million loss in the prior year, while increasing investment in research and development to $3.7 million. Subsequent to the fiscal year-end, Virax completed the exercise of preferred investment options for gross proceeds of approximately $3.3 million and entered into a commercial supply agreement with Fosun Diagnostics for its ImmuneSelect product across six Southeast Asian markets.
Key figures
- Net Income
- -5.0 million
- Total Debt
- 1.0 million
- Total Assets
- 8.3 million
- Cash Position
- 6.4 million
- Ga Expenses
- 2.7 million
- Rd Expenses
- 3.7 million
- Share Price
- 3.74
- Financing Proceeds
- 3.3 million
- Reverse Split Ratio
- 1-for-25
- Shareholders Equity
- 7.3 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.